October 22, 2016 3:27 AM ET

Healthcare Equipment and Supplies

Company Overview of HyperBranch Medical Technology, Inc.

Company Overview

HyperBranch Medical Technology, Inc., a medical device company, develops and markets products primarily for the traumatic or surgically induced wound market. It offers OcuSeal, a liquid ocular bandage for direct application on the surface of the eye to form an ocular bandage, thereby covering an opening in the eye and providing an immediate protective barrier; and Adherus Dural Sealant, which is used as an aid in dural repair in cranial and spinal surgeries, such as the treatment of intracranial aneurysms, tumors, and spinal disc disease. The company also provides Adherus Hernia Mesh Fixation, a device used as a replacement for tacks, staples, sutures, and 'O' rings in hernia repair procedur...

800-12 Capitola Drive

Durham, NC 27713-4410

United States

Founded in 2003





Key Executives for HyperBranch Medical Technology, Inc.

Chief Executive Officer, Chief Operations Officer and Director
Age: 62
Age: 62
Co-Founder and Chief Scientific Officer
Principal and Director
Medical Director and Member of Advisory Board
Compensation as of Fiscal Year 2016.

HyperBranch Medical Technology, Inc. Key Developments

HyperBranch Medical Technology, Inc. Wins Decision against Integra LifeSciences

HyperBranch Medical Technology, Inc. announced that it has defeated a motion by Integra LifeSciences to preliminarily enjoin HyperBranch from selling its Adherus AutoSpray Dural Sealant product. The Court’s opinion relied, in part, on evidence that “unquestionably shows that [Integra’s] DuraSeal’s applicator was associated with significant problems; the [Adherus] AutoSpray product’s applicator did not have such problems.” HyperBranch began selling Adherus AutoSpray Dural Sealant in the United States in July 2015 after receiving FDA approval. In September 2015, Integra sued HyperBranch for alleged patent infringement in the U.S. District Court for the District of Delaware. Integra also filed a motion seeking a preliminary injunction to prevent HyperBranch from selling Adherus AutoSpray Dural Sealant during the pendency of the lawsuit. On September 29, 2016, Chief Judge Leonard P. Stark adopted the Report and Recommendation of Magistrate Judge Christopher J. Burke and denied Integra’s motion. Rejecting Integra’s argument that it would suffer irreparable harm as a result of HyperBranch’s alleged patent infringement, the Court found: The record is replete with compelling evidence that the AutoSpray product is an attractive choice over DuraSeal due to a feature that undisputedly has nothing to do with the asserted patents—its applicator. This evidence unquestionably shows that: DuraSeal’s applicator was associated with significant problems; the AutoSpray product’s applicator did not have such problems; and this would be an important reason why physicians and hospitals would choose the AutoSpray product over the DuraSeal product. The Court also found that the public interest favors keeping Adherus AutoSpray Dural Sealant on the market during the pendency of the litigation. Citing testimony from three neurosurgeons with a combined 93+ years of experience, who “each expresse[d] a clear preference for the AutoSpray product,” along with documents from Integra that were “rife with references to the AutoSpray product’s improved applicator [and] to unresolved problems with DuraSeal,” the Court provided its rationale: there are only two FDA-approved dural sealant products for cranial procedures that are available in the United States market-Integra’s product and HyperBranch’s product; the products’ use has a real effect on the health of patients who have undergone serious surgical procedures; the record indicates that at least some number of physicians prefer HyperBranch’s product to Integra’s product (and does not contain much, if any, evidence regarding surgeons who prefer the DuraSeal product over the AutoSpray product); and the record suggests that the DuraSeal product has deficiencies that the AutoSpray product does not suffer from. The lawsuit will continue, with a trial scheduled to begin on April 16, 2018. In responding to the complaint, HyperBranch has denied Integra’s infringement allegations, asserted various defenses, including invalidity of the patents at issue, and requested an award of its attorneys’ fees and other litigation costs. HyperBranch intends to continue to defend itself vigorously against Integra’s claims and is confident that it will prevail on the merits.

Integra LifeSciences Holdings Corporation Files Lawsuit Against HyperBranch Medical Technology, Inc

On September 15, 2015, Integra LifeSciences Holdings Corporation announced that the company filed a lawsuit in the U.S. District Court for the District of Delaware against HyperBranch Medical Technology, Inc. The lawsuit alleges that HyperBranch's Adherus Autospray Dural Sealant, Adherus Dural Sealant, and Adherus Spinal Sealant infringe patents that the Company licenses from Incept LLC. The lawsuit contends that U.S. Patents 7,009,034; 7,592,418; 7,332,566; 6,566,406; 8,003,705; and 8,535,705 are infringed by HyperBranch's Adherus products. The lawsuit asks the court to enjoin HyperBranch from continuing to make, sell, and offer to sell the Adherus products and to grant treble damages for willful infringement.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HyperBranch Medical Technology, Inc., please visit www.hyperbranch.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.